Tucatinib

  • Medicine Name: Tukysa
  • API: Tucatinib
  • Dosage Form: 60/120 Tablets
  • Strength: 50 mg/150 mg
  • Manufacturer Name: Seattle Genetics, Inc.
Get Price

Description

Tukysa (tucatinib 50 mg/150 mg) is a kinase inhibitor approved for use in conjunction with trastuzumab and capecitabine to treat adult patients with advanced unresectable or metastatic HER2-positive breast cancer. This includes those with brain metastases, previously treated with one or more anti-HER2-based regimens. Additionally, tucatinib, in combination with trastuzumab, is used to manage adult patients with RAS wild-type HER2-positive unresectable or metastatic colorectal cancer. This indication applies to cases that have progressed following treatment with fluoropyrimidine-, oxaliplatin-, and irinotecan-based chemotherapy.

Posology & Administration:

Metastatic Breast Cancer: The recommended dosage of Tucatinib is 300 mg taken orally (by mouth) twice daily in combination with trastuzumab and capecitabine until there is evidence of disease progression or unacceptable toxicity.

Unresectable or Metastatic Colorectal Cancer: The recommended dosage of Tucatinib is 300 mg taken orally (by mouth) twice daily in combination with trastuzumab until there is evidence of disease progression or unacceptable toxicity.

Swallow the tablets whole and do not chew, crush, or split before swallowing. Do not ingest tablets if it is broken, cracked, or not otherwise intact. Administer the Tukysa dosage around 12 hours apart and at the same time each day with or without a meal. If the patient vomits or misses a dose, the patient should take the next dose at its usual scheduled time. When given along with Tukysa, the recommended dosage of capecitabine is 1000 mg/m2 orally twice daily taken within 30 minutes following a meal. Tukysa and capecitabine can be taken at the same time.

Important Safety Information

diarrhea: Tukysa 50 mg/150 mg tablets can cause severe diarrhea, which may lead to dehydration and electrolyte imbalances. Patients should be monitored for diarrhea and advised to stay hydrated. Antidiarrheal medications may be prescribed, and treatment may need to be interrupted or discontinued if diarrhea is severe or persistent.

Hepatotoxicity: Treatment with this medication may result in hepatotoxicity, characterized by elevated liver enzymes and liver dysfunction. Liver function tests should be performed regularly during treatment, and therapy should be interrupted or discontinued if hepatotoxicity occurs.

Interstitial Lung Disease (ILD): ILD, including pneumonitis, can occur with this therapeutic drug. Patients should be monitored for respiratory symptoms, such as cough or dyspnea, and treatment should be interrupted or discontinued if ILD is suspected.

Embryo-Fetal Toxicity: Tucatinib tablets can cause fetal harm when administered to pregnant women. Pregnancy should be avoided during treatment, and effective contraception should be used in women of childbearing potential.

Cardiotoxicity: This medicinal product may lead to cardiotoxicity, including decreases in left ventricular ejection fraction (LVEF) and congestive heart failure (CHF). Cardiac function should be assessed before starting treatment and monitored regularly during therapy.

Drug Interactions: Tukysa pills may interact with other medications, potentially affecting their efficacy or increasing the risk of adverse reactions. Patients should inform their healthcare provider of all medicines they are taking, including prescription, over-the-counter, and herbal supplements.

Documentation & Availability

What documents are required to import TUKYSA to India? TUKYSA (Tucatinib) Tablets can be imported by patients or government hospitals on the name of the patients only. The following documentation is needed to import the product:
  • A valid prescription from a qualified doctor.
  • Patients diagnostic reports
  • Patient ID proof (issued by the government of India)
How does the order be confirmed? The order will be confirmed only after the receipt of:
  • Valid prescription of Doctor
  • Import permit if applicable
Is TUKYSA available in India? TUKYSA (Tucatinib Tablet) is a (prescription drug, prescription medication, or prescription medicine) pharmaceutical drug that legally requires a medical prescription to be dispensed. IPN (Indian Pharma Network) helps import cancer medicines on the named patient supply (NPS). Indian Pharma Network is the facilitator providing input
  • On availability of Tukysa in India ( Kolkata, Hyderabad, Mumbai, Chennai, Ahmedabad, Delhi, Bangalore, Pune etc.)
  • Medicine Price.
  • Finding Authentic and reliable sources from USA, Canada, Europe, and Australia
  • Ensuring 100% transparency.
TUKYSA can be made available to patients, doctors, and hospitals in Mumbai, Goa, Kolkata, Hyderabad, Chennai, Ahmedabad, Delhi, Bangalore, Srinagar, Jammu, Jaipur, Chandigarh, Ludhiana, Noida, Gurgaon, Lucknow and Pune and other cities in India. The order will be confirmed only after the receipt of a valid prescription from the doctor and an import permit. TIP (The Indian Pharma) can facilitate the supply of TUKYSA (prescription medicines) to all locations in the world and India after fulfilling the legal requirement (if applicable). Please contact +91-9310090915 | Toll-Free No: 1800-889-1064 or write us at info@theindianpharma.com for the price of Tukysa in India. We guarantee quality and delivery in every corner of the world as per the buyer’s requirements.

Sourcing & Delivery

The Indian Pharma (TIP) can source TUKYSA (Cancer Treatment Medicines) from across the globe and can supply. TIP offers its customers worldwide access to the best available treatment.

The Indian Pharma (TIP) has the potential to dispense any valid prescription in the shortest possible time. All prescriptions are dispensed and checked by registered pharmacists and dispatched to the Patient’s address only from New Delhi, India.

FAQs

What does Tukysa contain as an active substance?

Tukysa contains the active substance Tucatinib.

How is Tukysa supplied?

Tukysa is supplied as Tablets: 50 mg and 150 mg for oral administration/use. It is available by prescription only.

What are the common side effects of Tukysa?

Common side effects of Tukysa may include diarrhea, nausea, fatigue, hepatotoxicity, vomiting, rash, stomatitis, decreased appetite, abdominal pain, headache, palmar-plantar erythrodysesthesia, and anemia.

How much does Tukysa cost in India?

Get the best Tukysa cost in India. If you want to buy it online, then THE INDIAN PHARMA (TIP) can help you access this medicinal product at the most competitive price in India through legal channels.

How to store Tukysa?

Store at controlled room temperature, 20 to 25°C (68 to 77°F); excursions permitted from 15 to 30°C (59 to 86°F). Dispense in original container only. Store in the original container to protect from moisture.

Is the Tukysa Tablet Available In India?

Tukysa is an imported medicine that is not readily available in India. It can be imported against a valid prescription and import permit. THE INDIAN PHARMA (TIP) can facilitate the supply of Tukysa Tablets after fulfilling the legal requirement (if applicable). Please contact us via +919310090915 or TOLL-FREE: 1800-889-1064 or write to us at info@theindianpharma.com to buy Tukysa online in India.

Can I get Tukysa even if I am not based in India?

THE INDIAN PHARMA (TIP) helps patients access/import Tukysa (Tucatinib), not approved in their home country against the valid prescription and in conformity with local laws and regulations of their respective country.

Where can I get Tukysa at the best price?

To get the best Tukysa price in India and other countries, always buy this oral medication from a Pharmaceutical Wholesaler Company that is GDP-certified. Noida-based THE INDIAN PHARMA (TIP) can offer the best price for Tukysa (Tucatinib).

Is it safe to buy Tukysa online in India?

Yes, one can buy Tukysa tablets online from India-based The Indian Pharma (TIP) if this therapeutic drug is not registered or is unavailable in the country. We can facilitate the supply of Tukysa Tablets through legal channels.

×